Clinical trial · Interventional
Antithymocyte Globulin in Treating Patients Undergoing Stem Cell Transplant for Multiple Myeloma
A Phase II Study of Thymoglobulin in Patients With Multiple Myeloma Who Are Candidates for Allogeneic or Autologous Stem Cell Transplant
NCT00378768CI-TRIAL-00005846completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Biological therapies, such as antithymocyte globulin, may stimulate the immune system in different ways and stop cancer cells from growing. PURPOSE: This phase II trial is studying how well antithymocyte globulin works in treating patients undergoing stem cell transplant for multiple myeloma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Multiple Myeloma and Plasma Cell Neoplasm | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| anti-thymocyte globulin | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Response rate, as measured by International Bone Marrow Transplant Registry (IBMTR)/European Group for Blood and Marrow Transplantation (EBMT) Response Criteria, at 4 weeks
Secondary outcomes (2)
- measure
- Toxicity as assessed by NCI CTC v2.0
- measure
- Formation of antirabbit antibodies
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Histologically confirmed multiple myeloma * Candidate for autologous or allogeneic stem cell transplantation within 1 to 3 months after study treatment * Measurable disease, defined as serum monoclonal protein ≥ 1 g/dL OR urinary light chain excretion = 500 mg/24 hours * No malignant CNS disease PATIENT CHARACTERISTICS: * Life expectancy ≥ 6 months * Absolute neutrophil count ≥ 1,000/mm³ * Platelet count \> 50,000/mm³ * Creatinine ≤ 2 mg/dL * Hepatic function ≤ 2 times upper limit of normal * DLCO ≥ 50% * No active infection * No hypersensitivity to rabbit proteins * No symptomatic hyperviscosity syndrome * Negative pregnancy test PRIOR CONCURRENT THERAPY: * More than 28 days since prior chemotherapy, including prednisone (20 mg equivalent/day) * No prior anti-thymocyte globulin * No concurrent radiotherapy
References
Publications (0)
Data not yet available
No reference posted for this study.